3-{3-[1 -(4-DIMETHYLAMINOMETHYL-PHENYLAMINO)-1 -PHENYL-METH-(Z)-YLIDENE]-2-OXO-2,3-DIHYDRO-1 H-INDOL-6-YLL-PROPYNOIC ACID ETHYLAMIDE AND ITS USE IN THE TREATMENT OF CANCER
The present invention relates to 3-{3-[1-(4-Dimethylaminomethyl- phenylamino)-1-phenyl-meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1 H- indol-6-yll-propynoic acid ethylamide having the formula (I) below, to a process for the manufacture thereof, and to the use thereof in the treatment of diseases characterized by excessive or abnormal cell proliferation.
-
Page/Page column 88; 89
(2014/02/15)
CRYSTALLINE FORM OF A INDOLINONE DERIVATIVE AND ITS USE
A crystalline form of 3-{3-[1-(4-Dimethylaminomethyl-phenylamino)-1-phenyl-meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-6-yl}-propynoic acid ethylamide.
-
Paragraph 0494-0498
(2014/02/16)
INDOLINONE DERIVATIVES ANTICANCER COMPOUNDS
The invention describes indolinones derivatives as dual Aurora kinase / MEK inhibitors and their use in therapy.
-
Page/Page column 67
(2014/02/15)
Anticancer Compounds
The invention describes dual Aurora kinase/MEK inhibitors and their use in therapy.
-
Paragraph 0388-0389
(2014/02/16)
More Articles about upstream products of 1535204-23-9